Gabapentinoid Prescribing Trends in Australian Injury Claims

Understanding pregabalin and gabapentin escalation patterns and what they mean for your claims management

Published 3 April 2026

The Gabapentinoid Phenomenon in Your Claims

You've noticed the pattern. Gabapentinoids, primarily pregabalin and gabapentin, are prescribed more frequently in your injury claims and at higher doses than they were five years ago. Your claimants are taking these medications longer, and deprescribing them is challenging. You're funding gabapentinoid costs that exceed what you expected. This isn't coincidence. Gabapentinoid prescribing in Australian injury claims has shifted markedly, and understanding this shift helps you manage these medications strategically.

Gabapentinoids serve legitimate roles in injury management. They're evidence-based for neuropathic pain and have reasonable safety profiles when appropriately prescribed. However, current patterns show prescribing that extends beyond evidence-based indication and dosing, creating cost and duration concerns for your claims. Understanding the trends allows you to intervene strategically before gabapentinoid use becomes entrenched.

What Gabapentinoids Are and When They're Appropriate

Gabapentin and pregabalin are medications developed for neuropathic pain. Gabapentin is approved for neuropathic pain at doses up to 3600mg daily (though practical maximum is typically 1800-2400mg). Pregabalin is approved for neuropathic pain and generalized anxiety disorder at 150-600mg daily. Both are evidence-based for specific indications and appropriate when clearly indicated.

The appropriate question for you is not whether these medications are ever justified. They are. The question is whether current prescribing patterns in your claims align with evidence-based indication and dosing. And increasingly, the answer is no.

Current Prescribing Patterns in Australian Injury Claims

Your observation of changing gabapentinoid prescribing reflects real trends. Consider these patterns:

Dose Escalation Beyond Guidelines

Australian therapeutic guidelines suggest gabapentin maximum 1800mg daily and pregabalin maximum dose of 600mg daily. You're seeing claimants on gabapentin 2400mg or 3600mg daily, substantially above guideline recommendations. You're seeing pregabalin 750mg or 900mg daily when guidelines cap at 600mg. These escalations don't reflect evidence-based dose optimization. They reflect dose escalation continuing beyond evidence support.

Broad Indication Application

Gabapentinoids are approved for neuropathic pain. You're seeing them prescribed for generalized pain, musculoskeletal pain, functional limitations, and anxiety where neuropathic pain pathology isn't clearly documented. The indication has broadened from neuropathic pain to general pain management in injury claims.

Extended Duration

Gabapentinoids are intended as long-term therapy for neuropathic pain, but with periodic reassessment of continued need. You're seeing claimants on these medications for years without documented reassessment or deprescribing consideration. The medications have become entrenched in chronic prescribing patterns.

Resistance to Deprescribing

When deprescribing is attempted, withdrawal effects and symptom rebound make it difficult. Your claimants report increased pain during gabapentinoid tapering, making them resistant to deprescribing attempts. This isn't necessarily problematic, but it does mean that early escalation creates long-term commitment to these medications.

Why Prescribers Are Escalating Gabapentinoids

You should understand the clinical reasoning behind gabapentinoid escalation, which is often legitimate:

• Neuropathic pain is genuinely difficult to manage and gabapentinoids often provide benefit where other options haven't worked
• Initial doses often provide incomplete symptom relief, creating pressure to escalate doses seeking better control
• Tolerance can develop, requiring dose increases to maintain effect
• Injury pain mechanisms often aren't purely neuropathic, so gabapentinoid benefit plateaus and prescribers escalate hoping higher doses will cross the benefit threshold
• Some prescribers use gabapentinoids as general pain management because opioid deprescribing is reducing opioid availability for pain control

These are real clinical pressures. Your prescribers aren't escalating gabapentinoids carelessly. However, the result is that dosing has shifted beyond evidence-based guidance. You need to address this through better indication clarity and dose optimization rather than assuming inappropriate prescribing.

Evidence Base for Current Gabapentinoid Dosing

Here's what evidence actually supports:

This framework helps you assess whether current gabapentinoid prescribing in your claims aligns with evidence. Doses above these ranges require specific documented justification.

The Dependence and Withdrawal Issue

Gabapentinoids can create dependence with chronic use, and withdrawal can be significant when medications are stopped. Claimants report rebound pain, anxiety, and sleep disturbance during gabapentinoid deprescribing. This isn't addiction (which gabapentinoids don't reliably cause), but it is physical dependence that makes deprescribing challenging.

This dependence creates a practical problem: once gabapentinoid doses are escalated, deprescribing becomes difficult because withdrawal effects perpetuate medication use. Your claimant becomes trapped in a regimen where reducing medication causes symptom rebound that your prescriber interprets as inadequate pain control justifying continued use. Early escalation to high doses creates long-term commitment to these medications.

Your Claims Management Strategy for Gabapentinoids

You should develop explicit guidelines for gabapentinoid management in your claims:

Cost Impact of Current Gabapentinoid Patterns

Understand that high-dose gabapentinoid use affects your costs substantially. Pregabalin at high dose is more expensive than at standard dose. Extended duration use multiplies costs. Deprescribing failure means ongoing cost commitment. A claimant on pregabalin 600mg daily is costing you significantly more than a claimant on 300mg daily, and the evidence benefit of doubling dose is limited.

Calculate gabapentinoid costs in your claims population. If average dose is creeping upward, you have a trend problem that medication review can address. If deprescribing is rarely successful, you have an indication that escalation during acute phases is limiting your options later.

Your Pharmacist's Gabapentinoid Assessment

When referring for medication review, specifically ask your pharmacist to assess:

• Is neuropathic pain pathology clearly documented, or is this general pain being treated with neuropathic pain medication?
• Is the current dose aligned with evidence-based guidance?
• Has lower dose been adequately trialed, or was dose escalation rapid?
• Is response to medication being objectively measured, or is medication continued by assumption?
• What is the deprescribing plan and likelihood of successful deprescribing?
• Could other medications addressing pain or function provide benefit with lower dependence risk?

Your pharmacist provides clinical assessment that helps you make strategic gabapentinoid management decisions early in your claim before escalation becomes entrenched.